CD19 and systemic lupus erythematosus: Consistent with prior reports of CD19-directed CAR T cell therapy in B cell malignancies, there appears to be only a mild to modest impact of anti-CD19 CAR T cells on pre-existing humoral immunity in SLE patients (Figures 2B, 2D, and S2).7